中药联合恩替卡韦降低HBeAg阳性慢性乙型肝炎停药后复发风险的多中心双盲随机对照试验
本研究为全国多中心、双盲、随机、安慰剂对照试验,计划纳入490例HBeAg阳性慢性乙型肝炎患者,1:1随机分配至中药颗粒(调肝补虚解毒颗粒)联合恩替卡韦0.5mg每日一次组或安慰剂联合恩替卡韦组,巩固治疗96周后停药观察24周,主要终点为试验结束时临床复发累积率。
要点
- 中药联合恩替卡韦巩固治疗96周,停药后观察24周,评估临床复发累积率。
- 研究设计为多中心、双盲、随机、安慰剂对照,计划纳入490例患者。
- 主要结局为试验结束时的临床复发累积率,复发后重启恩替卡韦治疗。
核心结论
- 该研究旨在观察中药联合恩替卡韦在HBeAg阳性慢性乙型肝炎患者中减少停药后复发风险的疗效。
- 这是首个在CHB人群中观察统一整合巩固治疗后停药复发效果的同类研究。
研究设计与样本
- 全国多中心、双盲、随机、安慰剂对照试验,为期120周。
- 计划纳入18家医院的490例合格中国HBeAg阳性CHB患者,按1:1随机分配至试验组和对照组。
- 试验组接受调肝补虚解毒颗粒联合恩替卡韦0.5mg每日一次巩固治疗96周;对照组接受中药颗粒安慰剂联合恩替卡韦0.5mg每日一次相同疗程。
- 巩固治疗后所有患者停用试验药物,随后24周密切监测,一旦出现临床复发即重启恩替卡韦治疗。
关键数值与推荐
- 主要结局为试验结束时的临床复发累积率。
- 巩固治疗疗程96周,停药后观察24周,总研究时长120周。
- 恩替卡韦剂量为0.5mg每日一次。
- 样本量计划为490例,随机比例1:1。
临床怎么用
- 对于HBeAg阳性CHB患者,可考虑在恩替卡韦基础上联合中药颗粒进行巩固治疗,以降低停药后复发风险。
- 停药后需密切监测24周,一旦临床复发应及时重启恩替卡韦治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nucleos(t)ide analogues (NAs) are the first-line option against chronic hepatitis B (CHB). NAs produce potent suppression of viral replication with a small chance of HBsAg seroclearance and a high risk of virological relapse after discontinuation. The combined therapy of NAs plus traditional Chinese medicine (TCM) is widely accepted and has been recognized as a prospective alternative approach in China. Based on preliminary works, this study was designed to observe the therapeutic effect of TCM plus entecavir (ETV) against HBeAg-positive chronic hepatitis B with respect to reducing the recurrence risk after NA withdrawal. METHODS/DESIGN: The study is a nationwide, multicenter, double-blind, randomized, placebo-controlled trial with a duration of 120 weeks. A total of 18 hospitals and 490 eligible Chinese HBeAg-positive CHB patients will be enrolled and randomly allocated into the experimental group and control group in a 1:1 ratio. Patients in the experimental group will be prescribed TCM formulae (Tiaogan-BuXu-Jiedu granules) plus ETV 0.5 mg per day for consolidation therapy for 96 weeks. Patients in the control group will be prescribed TCM granule placebo plus ETV 0.5 mg per day for the same course. After consolidation therapy, all patients will discontinue their trial drugs and be closely monitored over the next 24 weeks. Once clinical recurrence (CR) occurs, ETV treatment will be restarted. The primary outcome is the cumulative rate of CR at the end of this trial. CONCLUSION: This study is the first of its kind to observe therapeutic effects with respect to reducing recurrence after NA withdrawals after unified integrative consolidation therapy in the CHB population. TRIAL REGISTRATION: Chinese Clinical Trial Registry No. ChiCTR1900021232 . Registered on February 2, 2019.
引用
- Li X, Zhang L, Qiu M, et al. Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multicener, double-blind, randomized controlled trial in China. Trials. 2020. PMID: 32787905. doi:10.1186/s13063-020-04417-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。